Summary:
Click image to enlarge
This study is researching a way to minimize risk for children with a peanut allergy who accidentally ingest peanuts with a combination treatment of oral immunotherapy and an investigational product (dupilumab) or placebo in this indication.
This study will test how dupilumab works in the body, how safe it is to use, and how well it works when added to oral immunotherapy to minimize risk in children who ingest peanuts.
This study will last between 48 to 72 weeks.
No health insurance or doctor referral is needed to participate.
Qualified Participants Must:
• Have a history of a peanut allergy
• Be between the ages of 6 to 17 years old
• Have a positive skin prick test
• Meet certain safety laboratory tests
• Pass a peanut food challenge screening procedure
Qualified Participants May Receive:
- Compensation for time and travel
- Study-related care at no cost
- Study medication at no cost